We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights
GCVRZ

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

Back to rankings

106 hedge funds and large institutions have $80.4M invested in Sanofi Contingent Value Rights in 2018 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 19 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

6% more capital invested

Capital invested by funds: $76.1M → $80.4M (+$4.28M)

0% more funds holding

Funds holding: 106 → 106 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

26% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 19

Holders
106
Holders Change
–
Holders Change %
0%
% of All Funds
2.42%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
10
Increased
14
Reduced
19
Closed
9
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
-$722K

Top Buyers

Rank Fund Capital Flow
1
HCM
Highbridge Capital Management
New York
+$448K
2
DAM
DLD Asset Management
New York
+$322K
3
Citadel Advisors
Citadel Advisors
Florida
+$27.1K
4
WVP
Worth Venture Partners
New Jersey
+$14.5K
5
NGA
New Generation Advisors
Massachusetts
+$13.4K

Top Sellers

Rank Fund Capital Flow
1
PC
Pomelo Capital
New York
-$683K
2
GCM
Gruss Capital Management
New York
-$490K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$141K
4
JGC
J. Goldman & Co
New York
-$101K
5
CL
CSS LLC
Illinois
-$58K
Name Holding Trade Value Shares
Change 		Change in
Stake
YCM
26
Yakira Capital Management
Connecticut
$82K – – –
Susquehanna International Group
27
Susquehanna International Group
Pennsylvania
$66K -$141K -263,308 -68%
AL
28
Arnhold LLC
New York
$36K -$44.3K -82,585 -56%
UBS Group
29
UBS Group
Switzerland
$36K +$3.1K +5,776 +9%
Citadel Advisors
30
Citadel Advisors
Florida
$34K +$27.1K +50,544 +492%
GI
31
GAMCO Investors
Connecticut
$33K – – –
CI
32
Cowen Inc
New York
$30K +$9.98K +18,617 +49%
Korea Investment Corp
33
Korea Investment Corp
South Korea
$26K -$1.5K -2,800 -6%
Royal London Asset Management
34
Royal London Asset Management
United Kingdom
$24K – – –
ZIG
35
Zuckerman Investment Group
Illinois
$23K – – –
Ameriprise
36
Ameriprise
Minnesota
$19K +$176 +328 +0.9%
Morgan Stanley
37
Morgan Stanley
New York
$17K -$564 -1,052 -3%
CHAM
38
Clear Harbor Asset Management
Connecticut
$17K – – –
MCM
39
Mainstay Capital Management
Michigan
$14K +$169 +315 +315%
WVP
40
Worth Venture Partners
New Jersey
$14K +$14.5K +27,013 New
SDWMA
41
Schneider Downs Wealth Management Advisors
Pennsylvania
$13K – – –
Commonwealth Equity Services
42
Commonwealth Equity Services
Massachusetts
$11K -$617 -1,150 -5%
CS
43
Credit Suisse
Switzerland
$9K – – –
LPL Financial
44
LPL Financial
California
$9K +$3.05K +5,693 +51%
SC
45
Savant Capital
Illinois
$9K +$9.11K +16,993 New
FHA
46
Flagship Harbor Advisors
Massachusetts
$8K – – –
HK
47
Horizon Kinetics
New York
$8K – – –
MC
48
Moors & Cabot
Massachusetts
$8K – – –
RWP
49
RWA Wealth Partners
Massachusetts
$8K – – –
WEC
50
Winslow Evans & Crocker
Massachusetts
$8K – – –
1
2
3 4

GCVRZ Hedge Fund Activity: Q3 2018 in Review

106 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q3 2018, worth a combined $80.4M — up 5.6% from $76.1M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new GCVRZ positions and 9 closed out — a net gain of 1 holder — while 14 added to existing stakes and 19 trimmed.

The largest buyer was Highbridge Capital Management, adding an estimated $448K. The largest seller was Pomelo Capital, exiting entirely with an estimated $683K sold.

  • 106 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q3 2018, unchanged from Q2 2018.
  • Funds reported $80.4M of Sanofi Contingent Value Rights stock for Q3 2018, up 5.6% quarter-over-quarter.
  • 10 funds opened new Sanofi Contingent Value Rights positions in Q3 2018 and 9 closed out, a net change of +1 holder.
  • The largest Sanofi Contingent Value Rights buyer in Q3 2018 was Highbridge Capital Management, an estimated $448K added.
  • The largest Sanofi Contingent Value Rights seller in Q3 2018 was Pomelo Capital, an estimated $683K sold.

Based on aggregated 13F filings for Q3 2018.